Zydus Cadila has received the final approval from the United States Food and Drugs Administration (USFDA) to Bupropion Hydrochloride Extended-release Tablets USP (XL) in the strength of 300 mg. The drug falls in the anti-depressants segment. The estimated sales in 2013 as per IMS for Bupropion Hydrochloride Extended-release Tablets USP (XL), 300 mg were $255.9 million. The total market for Bupropion was estimated at $526.7 million. The group now has 87 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.
Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
